1624 / 1983
Radiation Boost for Ductal Carcinoma In Situ (DCIS) After Whole Breast Radiation
Therapy (WBRT) Improves Local Control,
Conclusions:
These findings suggest that the DCIS-boost results in a small, statistically significant benefit
in decreasing long-term IBTR of similar magnitude to boost for invasive cancers
•
This benefit appears to be independent of:
–
Tamoxifen use
–
Definition of negative margins
•
Similar to anticipated benefits seen in magnitude and age trends as with invasive cancers
DCIS treatment decisions are complex; Tailor to:
Clinical-pathologic features & tumor biology
Patient preferences
Anticipated longevity
These data support the use of a boost in DCIS
A boost should be considered for DCIS for patients undergoing WBRT, with life expectancies
10-15+ years
Moran MS, et al, JAMA Oncol 2017